Singleton pregnancy losses before gestational week 22 among patients with autoimmune disorders and methylenetetrahydrofolate reductase polymorphisms
- PMID: 35001885
- DOI: 10.3233/HAB-211517
Singleton pregnancy losses before gestational week 22 among patients with autoimmune disorders and methylenetetrahydrofolate reductase polymorphisms
Abstract
Background: The rates of pregnancy losses (PLs) are increased by maternal risk factors such as autoimmune disorders (AD) and methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms.
Objective: To evaluate singleton PLs before gestational week (gw) 22 among patients with AD and MTHFR polymorphisms.
Methods: Totally, 1108 singleton pregnancies in 243 women were categorized as: 1) 148 pregnancies in 33 patients with AD, 2) 316 pregnancies in 66 patients with MTHFR polymorphisms, 3) 644 pregnancies in 144 patients with AD +MTHFR polymorphisms. PLs were classified into subgroups: a) Chemical Pregnancy(CP), b) Blighted Ovum(BO), c) gw ⩽ 10, d) gw11-14 e) gw15-22, f) Ectopic Pregnancy(EP), g) Trophoblastic Disease(TD). Obstetric histories were compared using Beksac Obstetrics Index (BOI): [number of living child + (π/10)]/gravida.
Results: PL rates before gw22 were 39.2% (58/148), 33.2% (105/316), and 36.3% (234/644) in AD, MTHFR, and AD +MTHFR groups, respectively (p= 0.421). The rate of Pre-Prenatal Screening Period fetal losses (CP + BO + gw ⩽ 10 fetal losses + EP + TD) were 84.8%, 75.9%, and 77.8% in AD, MTHFR, and AD +MTHFR, respectively (p= 0.264). Gravidity ⩽ 4 versus those with gravidity ⩾ 5 had statistically significant differences in BOI (p< 0.001).
Conclusions: PL rate before gw22 among singleton pregnancies with AD and/or MTHFR polymorphisms was 35.8%. The clinical findings seem to be more complicated in patients with gravidity ⩾ 5.
Keywords: Autoimmune disorders; blighted ovum; chemical pregnancy; methylenetetrahydrofolate reductase polymorphisms; miscarriage; pregnancy loss.
Similar articles
-
Relationship of Cholelithiasis and Urolithiasis with Methylenetetrahydrofolate Reductase Polymorphisms.J Invest Surg. 2021 Oct;34(10):1104-1107. doi: 10.1080/08941939.2020.1742402. Epub 2020 Mar 31. J Invest Surg. 2021. PMID: 32228104
-
Comparison of different types of twin pregnancies in terms of obstetric and perinatal outcomes: association of vanished twins with methylenetetrahydrofolate reductase (MTHFR) polymorphism(s).J Assist Reprod Genet. 2018 Dec;35(12):2149-2154. doi: 10.1007/s10815-018-1346-7. Epub 2018 Oct 25. J Assist Reprod Genet. 2018. PMID: 30362058 Free PMC article.
-
Common Methylenetetrahydrofolate Reductase Polymorphisms (A1298C & C677T) in Ectopic Trophoblasts and Methotrexate Treatment Failure in Tubal Pregnancies.Ginekol Pol. 2018;89(10):536-540. doi: 10.5603/GP.a2018.0091. Ginekol Pol. 2018. PMID: 30393840
-
Methylenetetrahydrofolate reductase and transcobalamin genetic polymorphisms in human spontaneous abortion: biological and clinical implications.Reprod Biol Endocrinol. 2004 Feb 17;2:7. doi: 10.1186/1477-7827-2-7. Reprod Biol Endocrinol. 2004. PMID: 14969589 Free PMC article. Review.
-
Methylenetetrahydrofolate reductase (MTHFR) C677T/A1298C polymorphisms and susceptibility to Parkinson's disease: a meta-analysis.J Neurol Sci. 2013 Dec 15;335(1-2):14-21. doi: 10.1016/j.jns.2013.09.006. Epub 2013 Sep 12. J Neurol Sci. 2013. PMID: 24064257 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous